CSPG5

Summary

CSPG5 (chondroitin sulfate proteoglycan 5, HGNC:2467) is a protein-coding gene on chromosome 3p21.31, encoding Chondroitin sulfate proteoglycan 5 (O95196). May function as a growth and differentiation factor involved in neuritogenesis.

The protein encoded by this gene is a proteoglycan that may function as a neural growth and differentiation factor. Several transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 10675 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 94 total
• MANE Select transcript: NM_006574

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2467
Approved symbol	CSPG5
Name	chondroitin sulfate proteoglycan 5
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Aliases	NGC
Ensembl gene	ENSG00000114646
Ensembl biotype	protein_coding
OMIM	606775
Entrez	10675

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000264723, ENST00000383738, ENST00000456150, ENST00000465441, ENST00000610462

RefSeq mRNA: 5 — MANE Select: NM_006574 NM_001206942, NM_001206943, NM_001206944, NM_001206945, NM_006574

CCDS: CCDS2757, CCDS56252, CCDS56253, CCDS74930

Canonical transcript exons

ENST00000264723 — 5 exons

Exon	Start	End
ENSE00000750365	47576833	47577928
ENSE00001206522	47569152	47569227
ENSE00001206524	47572686	47572874
ENSE00003845836	47562238	47562761
ENSE00003845934	47578597	47578865

Expression profiles

Bgee: expression breadth ubiquitous, 201 present calls, max score 99.35.

FANTOM5 (CAGE): breadth broad, TPM avg 1.7536 / max 106.8560, expressed in 345 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
42049	1.2209	287
42048	0.2765	88
42050	0.1969	89
42051	0.0593	42

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	99.35	gold quality
pigmented layer of retina	UBERON:0001782	98.11	gold quality
frontal pole	UBERON:0002795	98.10	gold quality
retina	UBERON:0000966	98.09	gold quality
Brodmann (1909) area 23	UBERON:0013554	98.04	gold quality
choroid plexus epithelium	UBERON:0003911	97.86	gold quality
Brodmann (1909) area 10	UBERON:0013541	97.67	gold quality
CA1 field of hippocampus	UBERON:0003881	97.50	gold quality
orbitofrontal cortex	UBERON:0004167	97.25	gold quality
entorhinal cortex	UBERON:0002728	97.21	gold quality
Brodmann (1909) area 46	UBERON:0006483	97.15	gold quality
primary visual cortex	UBERON:0002436	97.07	gold quality
superior frontal gyrus	UBERON:0002661	96.99	gold quality
temporal lobe	UBERON:0001871	96.88	gold quality
amygdala	UBERON:0001876	96.78	gold quality
postcentral gyrus	UBERON:0002581	96.68	gold quality
occipital lobe	UBERON:0002021	96.67	gold quality
parietal lobe	UBERON:0001872	96.58	gold quality
middle frontal gyrus	UBERON:0002702	96.09	gold quality
nucleus accumbens	UBERON:0001882	96.07	gold quality
prefrontal cortex	UBERON:0000451	96.03	gold quality
caudate nucleus	UBERON:0001873	95.78	gold quality
frontal cortex	UBERON:0001870	95.70	gold quality
cerebral cortex	UBERON:0000956	95.64	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.62	gold quality
Ammon’s horn	UBERON:0001954	95.60	gold quality
telencephalon	UBERON:0001893	95.59	gold quality
neocortex	UBERON:0001950	95.58	gold quality
paraflocculus	UBERON:0005351	95.43	gold quality
cingulate cortex	UBERON:0003027	95.41	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-84465	yes	23.59
E-GEOD-135922	yes	14.27
E-ANND-3	no	2.10

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

36 targeting CSPG5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-5688	99.96	73.23	4504
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-498-5P	99.76	69.64	1807
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-548AV-5P	99.60	70.84	2107
HSA-MIR-548K	99.60	70.84	2107
HSA-MIR-486-5P	99.51	70.39	707
HSA-MIR-8054	99.48	70.81	2084
HSA-MIR-2115-3P	99.31	69.68	2026
HSA-MIR-520E-5P	99.27	68.90	1513
HSA-MIR-3973	99.20	69.19	1990
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-224-3P	98.91	68.42	1815
HSA-MIR-522-3P	98.91	68.56	1817
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-4659A-5P	98.03	66.42	819
HSA-MIR-4659B-5P	98.03	66.84	979
HSA-MIR-6791-3P	97.45	64.31	1123
HSA-MIR-6829-3P	97.45	64.31	1137

Literature-anchored findings (GeneRIF, showing 4)

• NGC IV, which was first found in the present study, had the shortest cytoplasmic domain among the four variants (PMID:16299773)
• neuroglycan C is a novel component of midkine receptors involved in process elongation (PMID:16901907)
• results suggest that NGC may be a novel candidate gene, and neuregulin signaling pathways may play an important role in schizophrenia (PMID:19367581)
• Chondroitin sulfate proteoglycan-5 forms perisynaptic matrix assemblies in the adult rat cortex. (PMID:32653642)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cspg5a	ENSDARG00000069981
danio_rerio	cspg5b	ENSDARG00000099793
mus_musculus	Cspg5	ENSMUSG00000032482
rattus_norvegicus	Cspg5	ENSRNOG00000020833

Protein

Protein identifiers

Chondroitin sulfate proteoglycan 5 — O95196 (reviewed: O95196)

Alternative names: Acidic leucine-rich EGF-like domain-containing brain protein, Neuroglycan C

All UniProt accessions (2): O95196, A0A087WUT8

UniProt curated annotations — full annotation on UniProt →

Function. May function as a growth and differentiation factor involved in neuritogenesis. May induce ERBB3 activation.

Subunit / interactions. Binds TNR and probably TNC. Interacts with ERBB3 and GOPC. Interacts with MDK; this interaction is independent of the presence of chondroitin sulfate chains and promotes elongation of oligodendroglial precursor-like cells.

Subcellular location. Cell membrane. Synaptic cell membrane. Endoplasmic reticulum membrane. Golgi apparatus membrane. Cell surface. Secreted.

Tissue specificity. Detected in cerebrospinal fluid (at protein level). Detected in urine (at protein level). Expressed in brain (at protein level).

Post-translational modifications. N-glycosylated. O-glycosylated; contains chondroitin sulfate glycans. Part-time proteoglycan, expressed in part as a proteoglycan exhibiting chondroitin sulfate glycans and in part as a non-proteoglycan form. The relative amount of both forms depends on tissues and tissue maturation. Phosphorylated; in intracellular and extracellular parts.

Miscellaneous. Different forms of various molecular weight have been observed. Such forms are possibly due to different levels of glycosylation, phosphorylation and/or protein cleavage.

Isoforms (3)

UniProt ID	Names	Canonical?
O95196-1	1	yes
O95196-2	2, CSPG5-I
O95196-3	3, CSPG5-II

RefSeq proteins (5): NP_001193871, NP_001193872, NP_001193873, NP_001193874, NP_006565* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009505	Neural_ProG_Cyt	Domain
IPR010555	CSPG5_S_attach_dom	Domain

Pfam: PF06566, PF06567

UniProt features (28 total): region of interest 6, modified residue 4, glycosylation site 4, disulfide bond 3, topological domain 2, splice variant 2, sequence variant 2, signal peptide 1, chain 1, compositionally biased region 1, transmembrane region 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95196-F1	52.52	0.11

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 467, 475, 483, 543

Disulfide bonds (3): 374–387, 381–397, 399–412

Glycosylation sites (4): 38, 57, 117, 165

Function

Pathways and Gene Ontology

Reactome pathways

10 pathways

ID	Pathway
R-HSA-1971475	Glycosaminoglycan-protein linkage region biosynthesis
R-HSA-2022870	CS-GAG biosynthesis
R-HSA-2022923	DS-GAG biosynthesis
R-HSA-2024101	CS/DS degradation
R-HSA-3560783	Defective B4GALT7 causes EDS, progeroid type
R-HSA-3560801	Defective B3GAT3 causes JDSSDHD
R-HSA-3595172	Defective CHST3 causes SEDCJD
R-HSA-3595174	Defective CHST14 causes EDS, musculocontractural type
R-HSA-3595177	Defective CHSY1 causes TPBS
R-HSA-4420332	Defective B3GALT6 causes EDSP2 and SEMDJL1

MSigDB gene sets: 186 (showing top): GNF2_RTN1, BROWNE_HCMV_INFECTION_8HR_UP, GOBP_GLIAL_CELL_DEVELOPMENT, GOBP_REGULATION_OF_EXOCYTOSIS, GOCC_CELL_SURFACE, GOBP_NEUROTRANSMITTER_TRANSPORT, GOBP_REGENERATION, GOBP_NEUROGENESIS, GOMF_GROWTH_FACTOR_ACTIVITY, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_RESPONSE_TO_AXON_INJURY, HASLINGER_B_CLL_WITH_11Q23_DELETION, GOBP_POSITIVE_REGULATION_OF_SUBSTRATE_ADHESION_DEPENDENT_CELL_SPREADING, GOBP_CELL_CELL_SIGNALING, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT

GO Biological Process (10): cytoskeleton organization (GO:0007010), nervous system development (GO:0007399), intracellular transport (GO:0046907), cell projection morphogenesis (GO:0048858), glial cell projection elongation (GO:0106091), positive regulation of substrate adhesion-dependent cell spreading (GO:1900026), regulation of synaptic vesicle exocytosis (GO:2000300), signal transduction (GO:0007165), cell differentiation (GO:0030154), modulation of chemical synaptic transmission (GO:0050804)

GO Molecular Function (2): growth factor activity (GO:0008083), protein binding (GO:0005515)

GO Cellular Component (16): Golgi membrane (GO:0000139), extracellular region (GO:0005576), endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), Golgi lumen (GO:0005796), plasma membrane (GO:0005886), cell surface (GO:0009986), membrane (GO:0016020), Golgi-associated vesicle membrane (GO:0030660), lysosomal lumen (GO:0043202), synapse (GO:0045202), postsynaptic membrane (GO:0045211), glutamatergic synapse (GO:0098978), GABA-ergic synapse (GO:0098982), endoplasmic reticulum (GO:0005783), synaptic membrane (GO:0097060)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Diseases associated with glycosaminoglycan metabolism	6
Chondroitin sulfate/dermatan sulfate metabolism	3
Glycosaminoglycan metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
synapse	3
Golgi apparatus	2
bounding membrane of organelle	2
cytoplasm	2
endomembrane system	2
intracellular membrane-bounded organelle	2
organelle organization	1
system development	1
intracellular anatomical structure	1
transport	1
cellular localization	1
establishment of localization in cell	1
cell morphogenesis	1
anatomical structure morphogenesis	1
cell projection organization	1
glial cell development	1
cell projection morphogenesis	1
positive regulation of cell-substrate adhesion	1
substrate adhesion-dependent cell spreading	1
regulation of substrate adhesion-dependent cell spreading	1
synaptic vesicle exocytosis	1
regulation of neurotransmitter secretion	1
regulation of regulated secretory pathway	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
cellular developmental process	1
chemical synaptic transmission	1
regulation of trans-synaptic signaling	1
receptor ligand activity	1
binding	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
intracellular organelle lumen	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1036 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CSPG5	LACRT	Q9GZZ8	911
CSPG5	FBLN2	P98095	790
CSPG5	PTN	P21246	605
CSPG5	PTPRZ1	P23471	594
CSPG5	MDK	P21741	579
CSPG5	PHF6	Q8IWS0	525
CSPG5	NCAN	O14594	519
CSPG5	ERBB3	P21860	512
CSPG5	GOPC	Q9HD26	512
CSPG5	EGF	P01133	499
CSPG5	RTN4R	Q9BZR6	461
CSPG5	BCAN	Q96GW7	449
CSPG5	NID1	P14543	447
CSPG5	MFAP3L	O75121	447
CSPG5	PAK1IP1	Q9NWT1	432

IntAct

19 interactions, top by confidence:

A	B	Type	Score
CSPG5	Gopc	psi-mi:“MI:0915”(physical association)	0.580
DLK1	TCAF2	psi-mi:“MI:0914”(association)	0.530
COLEC12	CSPG5	psi-mi:“MI:0914”(association)	0.530
HIRA	CSPG5	psi-mi:“MI:0914”(association)	0.530
CSPG5	HIRA	psi-mi:“MI:0914”(association)	0.530
APP	CSPG5	psi-mi:“MI:0407”(direct interaction)	0.440
PTPN2	GOLIM4	psi-mi:“MI:0914”(association)	0.350
CAPZB	ENAH	psi-mi:“MI:0914”(association)	0.350
DIAPH1	CSPG5	psi-mi:“MI:0914”(association)	0.350
SRP14	EIF3F	psi-mi:“MI:0914”(association)	0.350
SCN4A	C2CD4B	psi-mi:“MI:0914”(association)	0.350
NOG	TCAF2	psi-mi:“MI:0914”(association)	0.350
CSPG5	TCAF2	psi-mi:“MI:0914”(association)	0.350
MLX	BACH1	psi-mi:“MI:0914”(association)	0.350
SLC7A7	KLRG2	psi-mi:“MI:0914”(association)	0.350

BioGRID (40): CSPG5 (Affinity Capture-MS), CSPG5 (Affinity Capture-MS), CSPG5 (Affinity Capture-MS), CSPG5 (Affinity Capture-MS), CSPG5 (Affinity Capture-MS), CSPG5 (Affinity Capture-MS), CSPG5 (Reconstituted Complex), CSPG5 (Affinity Capture-Western), CSPG5 (Two-hybrid), GOPC (Two-hybrid), HS2ST1 (Affinity Capture-MS), CSPG5 (Affinity Capture-MS), SCAMP1 (Affinity Capture-MS), GALNT16 (Affinity Capture-MS), LMBR1 (Affinity Capture-MS)

ESM2 similar proteins: A1KXC4, B2RQL2, B2RTN2, O35188, O55145, O60667, O95196, P06484, P07141, P16382, P24394, P25918, P78423, Q29RT9, Q3SYS8, Q58CT8, Q5BK39, Q5FVQ5, Q5M871, Q5U2P6, Q63257, Q64322, Q68CR7, Q68DV7, Q6AXU5, Q6P1B3, Q6PNM1, Q6RFH4, Q71M36, Q863Z5, Q8BHB3, Q8BHE4, Q8BHW6, Q8BSU2, Q8C708, Q8IXW0, Q8JZQ0, Q8K0B3, Q8NET5, Q8R183

Diamond homologs: O95196, P70628, Q1XI86, Q71M36, Q80XH2, Q8JIR8, Q9BZV3, Q9DF69, Q9ERQ6, Q17R60, Q8R1W8, Q9ET62, Q9GMS5, P28826, Q16820, Q61847

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

94 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	86
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1023 predictions. Top by Δscore:

Variant	Effect	Δscore
3:47572681:CTCA:C	donor_gain	1.0000
3:47572684:A:AC	donor_gain	1.0000
3:47572685:C:CA	donor_gain	1.0000
3:47572695:CGCAG:C	donor_gain	1.0000
3:47572699:G:C	donor_gain	1.0000
3:47569150:A:AC	donor_gain	0.9900
3:47569151:C:CC	donor_gain	0.9900
3:47569232:T:C	acceptor_gain	0.9900
3:47569232:T:TC	acceptor_gain	0.9900
3:47572679:GACT:G	donor_loss	0.9900
3:47572680:A:AC	donor_gain	0.9900
3:47572680:ACTC:A	donor_loss	0.9900
3:47572681:C:CC	donor_gain	0.9900
3:47572683:C:CC	donor_loss	0.9900
3:47572684:ACT:A	donor_loss	0.9900
3:47572685:CT:C	donor_gain	0.9900
3:47572685:CTTG:C	donor_gain	0.9900
3:47577925:CGCG:C	acceptor_gain	0.9900
3:47577927:CG:C	acceptor_gain	0.9900
3:47577928:GCTG:G	acceptor_loss	0.9900
3:47577929:C:CC	acceptor_gain	0.9900
3:47577929:C:G	acceptor_loss	0.9900
3:47577930:T:C	acceptor_loss	0.9900
3:47577936:C:CT	acceptor_gain	0.9900
3:47569224:TTTG:T	acceptor_gain	0.9800
3:47569228:C:CC	acceptor_gain	0.9800
3:47572685:CTTGG:C	donor_gain	0.9800
3:47572874:CCT:C	acceptor_loss	0.9800
3:47572875:CTGCA:C	acceptor_loss	0.9800
3:47577924:ACGCG:A	acceptor_gain	0.9800

AlphaMissense

3499 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:47572850:C:A	W406C	1.000
3:47572850:C:G	W406C	1.000
3:47572812:A:C	F419C	0.999
3:47572832:G:C	C412W	0.999
3:47572833:C:A	C412F	0.999
3:47572833:C:G	C412S	0.999
3:47572833:C:T	C412Y	0.999
3:47572834:A:G	C412R	0.999
3:47572834:A:T	C412S	0.999
3:47572872:C:G	C399S	0.999
3:47572873:A:G	C399R	0.999
3:47572873:A:T	C399S	0.999
3:47576835:G:C	C397W	0.999
3:47576836:C:G	C397S	0.999
3:47576836:C:T	C397Y	0.999
3:47576837:A:G	C397R	0.999
3:47576837:A:T	C397S	0.999
3:47576865:G:C	C387W	0.999
3:47576866:C:G	C387S	0.999
3:47576867:A:G	C387R	0.999
3:47576867:A:T	C387S	0.999
3:47576883:A:C	C381W	0.999
3:47576884:C:G	C381S	0.999
3:47576884:C:T	C381Y	0.999
3:47576885:A:G	C381R	0.999
3:47576885:A:T	C381S	0.999
3:47576905:C:T	C374Y	0.999
3:47572719:A:G	L450P	0.998
3:47572728:A:G	L447P	0.998
3:47572733:C:A	K445N	0.998

dbSNP variants (sampled 300 via entrez): RS1000195787 (3:47564796 T>C), RS1000215023 (3:47572558 G>A,T), RS1000247418 (3:47572147 C>T), RS1000283650 (3:47578344 G>C,T), RS1000291210 (3:47563171 G>T), RS1000311574 (3:47576948 G>A,C,T), RS1000320632 (3:47576615 C>G,T), RS1000546612 (3:47571792 G>A), RS1000576965 (3:47570213 G>A), RS1000694659 (3:47578175 C>A), RS1000938529 (3:47563438 C>T), RS1000966172 (3:47570885 A>C), RS1001057040 (3:47564992 T>C), RS1001072814 (3:47578142 A>C,G), RS1001298900 (3:47576477 G>T)

Disease associations

OMIM: gene MIM:606775 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST008129_92	Body mass index	2.000000e-08
GCST011703_57	Smoking initiation	3.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0005670	smoking initiation

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
mercuric bromide	decreases expression, affects cotreatment	2
Panobinostat	affects cotreatment, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tretinoin	decreases expression	2
Valproic Acid	affects expression, increases expression	2
methylmercuric chloride	increases expression	1
bisphenol A	affects expression	1
sodium arsenite	increases expression	1
ferrous chloride	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
4-phenylbutyric acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	decreases expression	1
Acetaminophen	increases expression	1
Amphotericin B	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Coumestrol	increases expression, affects cotreatment	1
Lead	affects expression	1
Mercury	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Progesterone	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Thapsigargin	decreases expression	1
Okadaic Acid	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9CK	Ubigene HEK293 CSPG5 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.